CN119546752A - 炎性病况的治疗 - Google Patents
炎性病况的治疗 Download PDFInfo
- Publication number
- CN119546752A CN119546752A CN202380034277.3A CN202380034277A CN119546752A CN 119546752 A CN119546752 A CN 119546752A CN 202380034277 A CN202380034277 A CN 202380034277A CN 119546752 A CN119546752 A CN 119546752A
- Authority
- CN
- China
- Prior art keywords
- virus
- vlp
- protein
- galectin
- antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/7056—Lectin superfamily, e.g. CD23, CD72
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/36011—Togaviridae
- C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
- C12N2770/36123—Virus like particles [VLP]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/36011—Togaviridae
- C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
- C12N2770/36134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/36011—Togaviridae
- C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
- C12N2770/36141—Use of virus, viral particle or viral elements as a vector
- C12N2770/36143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2795/00—Bacteriophages
- C12N2795/00011—Details
- C12N2795/18011—Details ssRNA Bacteriophages positive-sense
- C12N2795/18111—Leviviridae
- C12N2795/18123—Virus like particles [VLP]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Hospice & Palliative Care (AREA)
- Cell Biology (AREA)
- Molecular Biology (AREA)
- Psychiatry (AREA)
- Gastroenterology & Hepatology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Toxicology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263332037P | 2022-04-18 | 2022-04-18 | |
| US63/332037 | 2022-04-18 | ||
| PCT/JP2023/015132 WO2023204148A1 (en) | 2022-04-18 | 2023-04-14 | Treatment of inflammatory conditions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN119546752A true CN119546752A (zh) | 2025-02-28 |
Family
ID=88308716
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202380034277.3A Pending CN119546752A (zh) | 2022-04-18 | 2023-04-14 | 炎性病况的治疗 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20230330209A1 (enExample) |
| EP (1) | EP4511479A4 (enExample) |
| JP (1) | JP2025513920A (enExample) |
| CN (1) | CN119546752A (enExample) |
| WO (1) | WO2023204148A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN118812696A (zh) * | 2024-08-21 | 2024-10-22 | 南通大学附属医院 | Galectin-3抗原表位肽、抗原、抗体及化学发光试剂盒 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI720946B (zh) * | 2014-08-08 | 2021-03-11 | 美商Vlp醫療股份有限公司 | 包含改質套膜蛋白質e3之類病毒粒子 |
| EP4326858A4 (en) * | 2021-04-23 | 2025-03-12 | VLP Therapeutics, Inc. | GALECTIN-TARGETED IMMUNOTHERAPY |
-
2023
- 2023-04-14 JP JP2024561984A patent/JP2025513920A/ja active Pending
- 2023-04-14 EP EP23791796.8A patent/EP4511479A4/en active Pending
- 2023-04-14 CN CN202380034277.3A patent/CN119546752A/zh active Pending
- 2023-04-14 WO PCT/JP2023/015132 patent/WO2023204148A1/en not_active Ceased
- 2023-04-17 US US18/301,542 patent/US20230330209A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20230330209A1 (en) | 2023-10-19 |
| EP4511479A4 (en) | 2026-07-08 |
| WO2023204148A1 (en) | 2023-10-26 |
| EP4511479A1 (en) | 2025-02-26 |
| JP2025513920A (ja) | 2025-04-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7701080B2 (ja) | アルファウイルスレプリコン粒子 | |
| CN105555306B (zh) | 免疫原性中东呼吸综合征冠状病毒(MERS-CoV)组合物和方法 | |
| KR20230049084A (ko) | Sars-cov-2 및 인플루엔자 조합 백신 | |
| KR20220010478A (ko) | 기도 감염의 치료 또는 예방용 서브유닛 백신 | |
| US9339535B2 (en) | Vaccines and immunopotentiating compositions and methods for making and using them | |
| BR112015030229B1 (pt) | Partícula semelhante a vírus compreendendo um polipeptídeo e um antígeno da malária, vetor, composições farmacêutica e de vacina, bem como molécula de ácido nucleico isolado | |
| CA3075990A1 (en) | Vaccines and methods of making and using vaccines for prevention of respiratory syncytial virus (rsv) infections | |
| US20230241203A1 (en) | Enhancing immune responses through targeted antigen expression | |
| US20130052226A1 (en) | Compositions and methods for preventing or treating a human parvovirus infection | |
| WO2023204148A1 (en) | Treatment of inflammatory conditions | |
| US20220347261A1 (en) | Galectin-targeting immunotherapy | |
| WO2024143497A1 (ja) | Cd153を標的とする医薬組成物 | |
| JP6675185B2 (ja) | 免疫誘導剤およびその製造方法 | |
| ES2282156T3 (es) | Vacuna de acido nucleico. | |
| WO2025084276A1 (ja) | 肥満の処置 | |
| CN106456742A (zh) | 用于治疗(包括预防)细小病毒感染及相关疾病的组合物和方法 | |
| RU2811991C2 (ru) | Субъединичная вакцина для лечения или предотвращения инфекции дыхательных путей | |
| OA20123A (en) | Alphavirus replicon particle. | |
| JPWO2005090576A1 (ja) | 百日咳感染症予防用dna構築物 | |
| BR112012032922A2 (pt) | construções de proteína homodimérica |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |